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Establishment and maintenance of the blood system relies on self-renewing hematopoietic stem
cells (HSCs) that normally reside in small numbers in the bone marrow niche of adult mammals.
This Review describes the developmental origins of HSCs and the molecular mechanisms that reg-
ulate lineage-specific differentiation. Studies of hematopoiesis provide critical insights of general
relevance to other areas of stem cell biology including the role of cellular interactions in develop-
ment and tissue homeostasis, lineage programming and reprogramming by transcription factors,
and stage- and age-specific differences in cellular phenotypes.Introduction
The blood system serves as a paradigm for understanding tissue
stem cells, their biology, and involvement in aging, disease, and
oncogenesis. Because mature blood cells are predominantly
short lived, stem cells are required throughout life to replenish
multilineage progenitors and the precursors committed to indi-
vidual hematopoietic lineages. Hematopoietic stem cells
(HSCs) reside as rare cells in the bone marrow in adult mammals
and sit atop a hierarchy of progenitors that become progres-
sively restricted to several or single lineages (Orkin, 2000). These
progenitors yield blood precursors devoted to unilineage differ-
entiation and production of mature blood cells, including red
blood cells, megakaryocytes, myeloid cells (monocyte/macro-
phage and neutrophil), and lymphocytes. As with all other stem
cells, HSCs are capable of self-renewal—the production of addi-
tional HSCs—and differentiation, specifically to all blood cell
lineages.
HSCs are defined operationally by their capacity to reconsti-
tute the entire blood system of a recipient. In general, prepara-
tion of patients for transplantation with donor bone marrow con-
taining HSCs entails destruction of host bone marrow by
irradiation or by treatment with high-dose cytotoxic drugs, in
part to provide ‘‘space’’ for donor HSCs within the marrow mi-
croenvironment (the niche) of the recipient. HSCs can be pro-
spectively identified by monoclonal antibodies directed to sur-
face markers, by dye efflux, or on the basis of their metabolic
properties; HSCs can be separated from more-committed pro-
genitors and other marrow cells by fluorescence-activated cell
sorting (FACS). With contemporary methods, HSCs may be
highly purified such that as few as one cell may provide long-
term (>4 months) hematopoietic reconstitution in a recipient.
Technical considerations regarding the assays for quantitation
of HSCs and evaluation of their function have recently been re-
viewed (Purton and Scadden, 2007). Because no ex vivo assays
can replace in vivo transplantation for measuring biological
activity of HSCs, characterizing cell populations based on theexpression of cell-surface markers cannot be considered
synonymous with determining their function. During stress or
other manipulations (such as in mutant animals), the surface
marker profile of HSCs and their progenitors may be distorted.
Here, we discuss the developmental origins of the hematopoi-
etic system and the molecular control of self-renewal and lineage
determination. The process of hematopoiesis is generally con-
served throughout vertebrate evolution. Manipulation of animal
models, such as the mouse and zebrafish, has complemented
and greatly extended studies of human hematopoiesis. Although
not an entirely ideal experimental system, partial reconstitution of
the blood system of immunodeficient mice (such as NOD/SCID
strains) has been commonly employed to study human hemato-
poiesis. The remarkable regenerative properties of human HSCs
arebest illustratedby thesuccess of marrow transplantation inhu-
man patients, a current mainstay of therapy for a variety of genetic
disorders, acquired states of bone marrow failure, and cancers.
Emergence of HSCs
In vertebrates, the production of blood stem cells is accom-
plished by the allocation and specification of distinct embryonic
cells in a variety of sites that change during development (Gallo-
way and Zon, 2003) (Figures 1 and 2). In mammals, the sequen-
tial sites of hematopoiesis include the yolk sac, an area
surrounding the dorsal aorta termed the aorta-gonad meso-
nephros (AGM) region, the fetal liver, and finally the bone marrow
(Figure 1). Recently, the placenta has been recognized as an ad-
ditional site that participates during the AGM to fetal liver period.
The properties of HSCs in each site differ, presumably reflecting
diverse niches that support HSC expansion and/or differentia-
tion and intrinsic characteristics of HSCs at each stage. For in-
stance, HSCs present in the fetal liver are in cycle, whereas adult
bone marrow HSCs are largely quiescent.
Although there is little dispute regarding where HSCs are
found during development, few topics have polarized investiga-
tors as much as the origin of HSCs. HSCs are derived fromCell 132, 631–644, February 22, 2008 ª2008 Elsevier Inc. 631
ventral mesoderm (see Review by C.E. Murry and G. Keller, page
661 of this issue). The contribution of each hematopoietic site
(such as the yolk sac and fetal liver) to circulating blood in the fe-
tus or adult was seemingly answered more than 25 years ago.
Recent studies in mice and zebrafish, however, challenge the
field with divergent views.
Multiple Waves of Hematopoiesis during Development
The initial wave of blood production in the mammalian yolk sac is
termed ‘‘primitive.’’ The primary function for primitive hemato-
poiesis is production of red blood cells that facilitate tissue oxy-
genation as the embryo undergoes rapid growth. The hallmark of
primitive erythroid cells is expression of embryonic globin pro-
teins. The primitive hematopoietic system is transient and rapidly
replaced by adult-type hematopoiesis that is termed ‘‘defini-
tive.’’
In mammals, the next site of hematopoietic potential is the
AGM region. Hematopoietic cells were first detected in the aorta
of the developing pig more than 80 years ago. Subsequently,
studies of chick-quail chimeras and diploid-triploid Xenopus em-
bryos demonstrated analogous AGM-like regions. Morphologi-
cal examination revealed that a sheet of lateral mesoderm mi-
grates medially, touches endoderm, and then forms a single
aorta tube. Clusters of hematopoietic cells subsequently appear
in the ventral wall. Similarly, an intraembryonic source of adult
HSCs in mice capable of long-term reconstitution of irradiated
hosts resides in the AGM region (Muller et al., 1994). At embry-
onic day 10.5, little HSC activity is detectable, whereas by day
11 engrafting activity is present.
Figure 1. Developmental Regulation of
Hematopoiesis in the Mouse
(A) Hematopoiesis occurs first in the yolk sac (YS)
blood islands and later at the aorta-gonad meso-
nephros (AGM) region, placenta, and fetal liver
(FL). YS blood islands are visualized by LacZ stain-
ing of transgenic embryo expression GATA-1-
driven LacZ. AGM and FL are stained by LacZ in
Runx1-LacZ knockin mice. (Photos courtesy of
Y. Fujiwara and T. North.)
(B) Hematopoiesis in each location favors the pro-
duction of specific blood lineages. Abbreviations:
ECs, endothelial cells; RBCs, red blood cells; LT-
HSC, long-term hematopoietic stem cell; ST-HSC,
short-term hematopoieticstem cell; CMP, common
myeloid progenitor; CLP, common lymphoid pro-
genitor; MEP, megakaryocyte/erythroid progenitor;
GMP, granulocyte/macrophage progenitor.
(C) Developmental time windows for shifting sites of
hematopoiesis.
Additional hematopoietic activity in the
mouse embryo was detected subse-
quently in other sites, including the umbil-
ical arteries and the allantois in which
hematopoietic and endothelial cells are
colocalized (Inman and Downs, 2007).
Umbilical veins lack hematopoietic po-
tential, suggesting that a hierarchy exists
during definitive hematopoiesis in which
HSCs arise predominantly during artery specification. In addi-
tion, significant numbers of HSCs are found in the mouse pla-
centa (Gekas et al., 2005; Ottersbach and Dzierzak, 2005), nearly
coincident with the appearance of HSCs in the AGM region and
for several days thereafter. Placental HSCs could arise through
de novo generation or colonization upon circulation, or both.
The relative contribution of each of the above sites to the final
pool of adult HSCs remains largely unknown.
Subsequent definitive hematopoiesis involves the colonization
of the fetal liver, thymus, spleen, and ultimately the bone marrow.
It is believed that none of these sites is accompanied by de novo
HSC generation. Rather, their niches support expansion of pop-
ulations of HSCs that migrate to these new sites. However, until
very recently (as discussed below), there has been no evidence
by fate mapping or direct visualization that HSCs from one site
colonize subsequent sites.
Hemangioblasts and Hemogenic Endothelium
A common origin for blood and vascular cells, the ‘‘hemangio-
blast,’’ was hypothesized a century ago, based largely on the in-
timate association of these lineages in the blood islands of the
developing yolk sac. Sharing of markers between blood and
blood vessel cells, and the impairment of both tissues in mu-
tants, such as the mouse flk1 knockout (Shalaby et al., 1997)
and zebrafish cloche (Stainier et al., 1995), are consistent with
a common origin. Clonal studies using in vitro differentiating
mouse embryonic stem (ES) cells provide the strongest evi-
dence in favor of the existence of hemangioblasts (Choi et al.,
1998). Furthermore, hemangioblast activity has been detected
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at the mid-streak stage of gastrulation and during the neural
plate stage but is extremely transient in vivo (Huber et al.,
2004). Despite these findings, formal proof of the hemangioblast
hypothesis requires direct demonstration that a single cell di-
vides asymmetrically to form blood and vascular derivatives
in vivo.
Clonal analysis in mouse chimeras, however, presents contra-
dictory evidence regarding the existence of the hemangioblast
(Ueno and Weissman, 2006). Three different, stably marked ES
cells were mixed and coinjected into host blastocysts. Accord-
ing to the hemangioblast hypothesis, each blood island of the
yolk sac should be clonally derived. However, in these experi-
ments more than a single ES cell often contributed to each blood
island of the chimeric mice. The existence of the hemangioblast
has also been addressed in zebrafish. A primitive wave of hema-
topoiesis occurs in a region called the intermediate cell mass
that contains erythroid cells surrounded by venous endothelial
cells (see Figure 2). Hematopoietic and endothelial markers seg-
regate between the 3- to 10-somite period of development. By
this time, there are few, if any, cells that might be considered he-
mangioblasts based on overlapping blood and blood vessel
gene expression. Alternatively, hemangioblasts could appear
before the 3-somite stage and also exhibit wider developmental
potential than solely blood and blood vessels. Ventral mesoder-
mal cells are dedicated specifically to hematopoietic and endo-
thelial fates. Fate-mapping studies have been performed in
which a caged fluorescent dye is injected into the zebrafish em-
bryo at the one-cell stage, and then at a later time the fluorescent
dye is uncaged in single cells using a laser. Individual cells ap-
pear dedicated to hematopoietic and endothelial lineages at
the 0- to 3-somite stage (Vogeli et al., 2006). However, other
cell fates may also be present at this early time. Similarly, smooth
muscle cells can be derived from populations of in vitro differen-
tiated mouse ES cells exhibiting blood and blood vessel fates
(Ema et al., 2003; Ema and Rossant, 2003). These studies sup-
port the existence of hemangioblasts, although it may be neces-
Figure 2. Hematopoietic Development in
the Zebrafish
(A) Hematopoiesis occurs first in the intermediate
cell mass (ICM) and subsequently in the aorta-go-
nad mesonephros (AGM) region and caudal hema-
topoietic tissue (CHT). Later hematopoietic cells
are found in the kidney as well as in the thymus.
In situ hybridization for GATA-1 at 30 hr (ICM), for
c-myb at 36 hr (AGM), for SCL/tal1 at days 4 and
6.5 (CHT), and forc-myb at day 6 (top view) to dem-
onstrate expression in the kidney marrow and thy-
mus. (Photos courtesy of X. Bai and T. Bowman.)
(B) Developmental time windows for hematopoi-
etic sites in the zebrafish.
sary to redefine the potential of these
cells to include additional lineages (such
as smooth muscle).
Principally based on morphology it has
been proposed that as the AGM forms,
‘‘hemogenic endothelial’’ cells in the ven-
tral wall of the aorta, rather than heman-
gioblasts, bud off HSCs. The program of hemogenic endothelial
cell development may be regulated differently from that of pre-
sumptive hemangioblasts, given that the transcription factor re-
quirements differ. For example, the transcription factor Runx1 is
necessary for blood formation from hemogenic endothelium but
not from yolk sac hemangioblasts (North et al., 1999, 2002). The
potential to generate hematopoietic, endothelial, and smooth
muscle cells has been attributed to another cell type, termed
the mesoangioblast, present in the aorta (Cossu and Bianco,
2003). Perhaps, the presumptive mesoangioblast might be a pre-
cursor of the hemogenic endothelial cell.
Other work has indicated that mesenchymal cell populations
in the subaortic region poke through the aorta and bud off
HSCs (Bertrand et al., 2005). As this occurs, mesenchymal cells
express endothelial-specific genes and ultimately express HSC-
associated markers. These observations suggest an alternative
model in which subaortic mesenchymal cells, which may also
have smooth muscle potential, rather than hemogenic endothe-
lial cells, are the source of future definitive HSCs.
Developmental Relationships between the Yolk Sac
and the AGM
As with mesodermal derivatives, all blood cells in embryonic, fe-
tal, and adult animals might arise from a small set of cells during
development. Evidence for and against this notion is present in
the literature. Fate mapping in the pre-gastrula Xenopus embryo
with fluorescent dye injected into individual blastomeres of the
32-cell embryo demonstrated that different blastomeres contrib-
ute to primitive hematopoiesis and definitive HSC production
(Ciau-Uitz et al., 2000). This finding contradicts the conclusion
derived from diploid-triploid chimeric frogs that ventral meso-
derm is the common origin of both primitive and definitive pop-
ulations (Turpen et al., 1997). Technical aspects of fate mapping
of the 32-cell embryo have been challenged (Lane and Sheets,
2002).
In situ hybridization and chimera studies in amphibians and
birds suggest that the yolk sac and the AGM are derived
Cell 132, 631–644, February 22, 2008 ª2008 Elsevier Inc. 633
independently and arise at different times in development
(Turpen et al., 1997). With short-term culture and subsequent
transplantation, mouse AGM tissue (isolated one day prior to
the appearance of HSCs in vivo) generates cells with the capac-
ity for long-term engraftment, whereas mouse yolk sac tissue
does not (Cumano et al., 1996; Medvinsky and Dzierzak, 1996).
The origin of HSCs in the AGM can be traced by Runx1 expres-
sion in the embryonic day 8.5 (E8.5) mouse embryo, just before
the onset of circulation. Because functional activity of stem cells
as determined by transplantation into irradiated adults occurs
much later (at day 11), it is possible that cells of the yolk sac col-
onize the AGM through the circulation. In fact, HSC-like activity
of yolk sac cells (as defined by a neonatal transplantation assay)
(Palis et al., 2001) is detected as early as day 9, although circu-
lation has started by that time. Conclusive resolution of the de-
velopmental relationship between cells of the yolk sac and
AGM requires direct visualization of the migration event. Further-
more, the specific assay used to determine stem cell activity for
one population of cells (such as immune reconstitution following
irradiation of adult animals) may not be appropriate for a different
stem cell population. Distinct host requirements, such as the use
of neonatal recipients for cells of the yolk sac, may be necessary.
Some of the intrinsic differences between cell populations, such
as developmental stage, ease of access, the local niche, and
whether they are dividing, may preclude a host transplant assay
from detecting engraftment and multilineage reconstitution.
Such questions will plague studies of other tissue stem cells,
as these stem cells are defined by functional and biological read-
outs.
Does the Yolk Sac Contain HSCs?
Based on cell fate mapping and transplantation experiments in
avian and amphibian species, the AGM has been widely viewed
as the principal site for HSC production during vertebrate devel-
opment. Accordingly, the yolk sac has often been relegated to
a subservient position, despite older experiments suggesting
that the yolk sac might be the source of adult hematopoiesis.
Metcalf and Moore cultured E7.5 mouse embryos from which
the yolk sac had been removed (Moore and Metcalf, 1970). Given
that no hematopoietic cells appeared in the fetal liver following
several days in culture, they concluded that the yolk sac was
the major site of adult blood formation for the embryo. Although
hematopoiesis in the yolk sac is largely primitive in character,
progenitors within the yolk sac do give rise to definitive type cells
in hematopoietic colony assays, an observation consistent with
a yolk sac origin for definitive cells. This view was supported
by other experiments in which specific donor-derived T cell pop-
ulations appeared following transplantation of cells of the yolk
sac into fetuses (Weissman et al., 1978).
In more recent work, Nishikawa and colleagues have also
challenged the dogma that the yolk sac lacks definitive hemato-
poietic stem cells (Samokhvalov et al., 2007). The fate of early
embryonic tissues was traced in transgenic mice in which
Runx1 regulatory elements drive expression of hormonally acti-
vated Cre recombinase. Administration of tamoxifen to pregnant
female mice at a particular developmental window permits the
fate of cells expressing Runx1 (visualized by activation of
a Flox-LacZ allele) to be assessed. Treatment of embryos at
E7.5 led to prominent marking of fetal liver cells and adult hema-
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E7.5 and the only tissue known to express Runx1 at E7.5, these
findings suggest that the yolk sac contains definitive HSCs (or
cells that may give rise to HSCs). These experiments were inter-
preted to support the yolk sac as a site of HSC formation prior to
the AGM, although consensus in the field is far from unanimous
(DeWitt, 2007). Diploid-triploid transplants in frogs reveal that
20% of adult blood in some animals is derived from the ventral
blood island (the equivalent to the yolk sac), providing indepen-
dent evidence that adult hematopoiesis may arise from the yolk
sac region. Despite this finding, it is also clear that the analogous
AGM region in Xenopus is the predominant contributor to adult
hematopoiesis. The precise origin of HSCs in the adult remains
a topic for further debate and study.
In Vivo Fate Mapping of Migrating Cells
Presumptive HSCs in the zebrafish express the transcription fac-
tors c-myb and Runx1 (see Figure 2). Caged fluorescein dye fate
mapping of AGM cells has revealed a new hematopoietic region,
the caudal hematopoietic tissue. Laser uncaging is targeted to
a region of cells in which transgenic expression of green fluores-
cent protein (GFP) driven by an HSC-specific promoter marks
HSCs in the AGM (Ferkowicz et al., 2003). This approach ensures
that laser uncaging occurs specifically within HSCs. Multiple
cells are uncaged and their fate is followed (Jin et al., 2007; Mur-
ayama et al., 2006). Uncaged cells of the AGM region that ex-
press CD41 (a surface marker of early HSCs) or c-myb appear
later as fluorescent cell populations in the caudal hematopoietic
tissue. The larval and adult site of hematopoiesis in the zebrafish
is the kidney. Later on in the fate map experiments, the larval kid-
ney becomes fluorescent, demonstrating that cells of the caudal
hematopoietic tissue colonize the kidney. In addition, fluores-
cence is detected in the thymus. Recent evidence suggests di-
rect population of thymic primordia through tissue planes, a find-
ing consistent with earlier experiments in birds showing migration
of progenitors to the thymus along the thoracic duct. Thus, pop-
ulation of the thymus may occur through circulation and direct
migration through tissues. Alternatively, the caudal hematopoi-
etic tissue may represent a site similar to the placenta or fetal liver
prior to the onset of definitive hematopoiesis in the kidney.
It is generally stated that HSCs of the fetal liver circulate to the
adult bone marrow and, hence, are the source of adult hemato-
poiesis in birds and mammals (see Review by D.J. Laird et al.,
page 612 of this issue). In contrast, developmental studies
reveal that the fetal liver and marrow are seeded at similar times
during development (Delassus and Cumano, 1996). Direct track-
ing of cellular migration is required to distinguish these possibil-
ities.
Pathways Involved in the Emergence of HSCs
The AGM has been characterized largely by morphology and
functional assays, but the pathways involved in HSC generation
remain incompletely defined. Studies of chick embryos demon-
strate that endoderm has a prominent role and secretes inducing
factors. Somitic mesoderm also contributes to the dorsal aspect
of the aorta, and the addition of factors—such as VEGF, TGF-b,
and FGF—to the somitic mesoderm leads to induction of hema-
topoietic tissue. In contrast, TGF-a and EGF suppressed forma-
tion of hematopoietic cells (Pardanaud and Dieterlen-Lievre,
1999).
Signaling pathways that regulate the induction of the AGM
have recently been uncovered in mouse and zebrafish. Notch 1
is required for artery identity and aortic HSC production (Kumano
et al., 2003). In the zebrafish mutant mindbomb that lacks Notch
signaling, Runx1 overexpression rescues HSC production
(Burns et al., 2005). Similarly, a Notch1 mutant is rescued by
Runx1 overexpression, suggesting that Runx1 lies downstream
or parallel to Notch signaling. Other pathways participate in the
process including CoupTF-II (Pereira et al., 1999), as well as
the CDX-HOX pathway (Davidson et al., 2003).
The Wnt/b-catenin and Notch-Delta signaling pathways influ-
ence the function of adult HSCs. Treatment of purified HSCs with
Wnt3a protein leads to a modest increase in engrafting cells
(Reya et al., 2003). Whereas a pulse of Wnt signaling appears
to induce HSCs, constitutive Wnt activation by stabilized b-cat-
enin leads to anemia, possibly by stem cell exhaustion as a con-
sequence of prolonged Wnt signaling (Kirstetter et al., 2006;
Scheller et al., 2006). Wnt signaling may be dispensable for adult
HSC homeostasis, given that conditional knockout of b- or
g-catenin in hematopoietic cells fails to affect HSC number or
engraftment potential (Cobas et al., 2004; Scheller et al., 2006).
Stimulation of the Notch pathway also increases HSC activity
and appears to be required for the increased self-renewal
upon Wnt activation (Duncan et al., 2005). In addition to the
Wnt and Notch pathways, new growth factors such as angio-
poietin-like proteins appear capable of supporting ex vivo
expansion of HSCs (Zhang et al., 2006).
A chemical genetic screen has recently revealed a role for the
prostaglandin pathway in the production of HSCs in the zebra-
fish. Treatment of embryos with prostaglandin E2 (PGE2) aug-
ments stem cell production (North et al., 2007), most likely
through the EP4 receptor, a G-coupled receptor specifically ex-
pressed in the aorta region and activated by PGE2 (Villablanca
et al., 2007). Prostaglandins also affect the homeostasis of defin-
itive adult hematopoiesis, as shown by irradiation recovery as-
says, 5-fluorouracil stimulation assays, and long-term hemato-
poietic reconstitution. Thus, the emergence of HSCs in the
aorta involves the prostaglandin pathway and the Notch-Runx
pathways, which appear to be independent based on genetic
relationships.
The hematopoietic system of the Drosophila embryo gener-
ates myeloid-like cells critical for tissue remodeling and engulf-
ment and phagocytosis of dead cells. The emergence of sites
of hematopoiesis during embryogenesis is remarkably similar
to that of vertebrates. Drosophila progenitors are also formed
adjacent to the circulatory system. Hematopoietic progenitors
bud off from head mesoderm. These myeloid cells are transient
and ultimately replaced by cells that bud off near the heart re-
gion and the great vessel. Vascular endothelial growth factor
(VEGF) ligands are required for derivation of adult hematopoi-
etic cells, as well as for attracting myeloid cells at specific sites
(Cho et al., 2002). Genetic analysis demonstrates that specific
signaling pathways, such as Notch, are required for the deriva-
tion of the lymph gland and a hemangioblast-like cell population
(Mandal et al., 2004). Recent studies demonstrate that the
lymph gland of the third instar larva of the fruit fly is patterned
and contains a signaling center that expresses Hedgehog li-
gand (Krzemien et al., 2007; Mandal et al., 2007). Hedgehog co-operates with Notch ligands expressed in these regions to form
a stem cell niche and regulates the cycling of hematopoietic
progenitors. The search is underway for a similar signaling cen-
ter in vertebrates. Hedgehog is also required for AGM hemato-
poiesis in the zebrafish (Gering and Patient, 2005). More re-
cently, studies of human embryonic stem cells have indicated
that factors such as hedgehog and bone morphogenetic
protein (BMP) promote blood production during in vitro differ-
entiation.
Niches
Stem cells depend on their microenvironment, the niche, for reg-
ulation of self-renewal and differentiation. Studies of Drosophila
testes and ovarian stem cells have led to formulation of concepts
that may be applicable to the niche in other tissues (Decotto and
Spradling, 2005; see also the Review by S.J. Morrison and A.C.
Spradling, page 598 of this issue). For instance, in the ovary,
a hub cell directly binds to a stem cell and regulates its self-re-
newal and differentiation, in part though BMP signaling (see Mini-
review by R.M. Cinalli et al., page 559 of this issue). In the testis,
an apical hub cell expresses the ligand Upd, an activator of the
JAK-STAT signaling pathway in adjacent germ cells to control
their self-renewal. By analogy to the Drosophila reproductive or-
gans, investigators have sought an equivalent of the hub cell for
the HSC.
As the site of hematopoiesis changes during vertebrate devel-
opment, the nature of the stem cell niche must also change. The
adult bone marrow niche (depicted in Figure 3) has received
most attention. Mutant mice in which the BMP pathway is dis-
rupted have increased numbers of osteoblasts and HSCs (Calvi
et al., 2003; Zhang et al., 2003). These findings suggest that os-
teoblasts may represent a critical component of the bone mar-
row niche for HSCs. As assessed by intravital microscopy,
HSCs appear to reside in the periosteal region of calverium mar-
row (Sipkins et al., 2005). Transplanted GFP-marked or LacZ-
marked HSCs appear to lodge adjacent to osteoblasts. Many
factors, including ligands for Notch receptors and N-cadherin,
are liberated by osteoblasts, although the contribution of these
to adult hematopoiesis remains to be established. The role of
N-cadherin as a mediator of interactions with osteoblasts (Zhang
et al., 2003), as well as the prominence of osteoblasts for HSC
adherence, have been challenged (Kiel et al., 2007). Recent find-
ings suggest that HSCs are maintained in a quiescent state
through interaction with thrombopoietin-producing osteoblasts
(Yoshihara et al., 2007). The association of HSCs with osteo-
blasts is countered by other studies that place HSCs adjacent
to vascular cells. The chemokine CXCL12 regulates the migra-
tion of HSCs to the vascular cells (now called the vascular niche)
(Kiel and Morrison, 2006). Taken together, these findings sug-
gest that HSCs reside in various sites within the marrow and
that their function might depend on their precise localization.
Much of the existing debate may be semantic, however, if the os-
teoblastic and vascular niches are intertwined and not physically
separate. Alternatively, HSCs may truly reside in distinct subre-
gions, which may endow them with different activities. Cellular
dynamics within the niche are relevant to clinical marrow trans-
plantation. For example, recent findings suggest that antibody-
mediated clearance of host HSCs facilitates occupancy of the
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niche and transplantation by exogenous HSCs (Czechowicz
et al., 2007).
How niches modulate self-renewal is a challenge for future
studies. The generation of premalignant myeloproliferative syn-
dromes in mice with abnormal niches underscores the need for
precise control in vivo (Perry and Li, 2007). Remarkably, the
site of hematopoiesis is not conserved in vertebrate evolution.
For instance, the site of adult hematopoiesis is the kidney in
fish. The frog forms adult blood in the liver, and birds and mam-
mals form blood in the marrow. In the frog Rana temporaria, the
site of hematopoiesis switches between the liver and bone mar-
row depending on the season (Maslova and Tavrovskaia, 1993).
Little is known regarding the nature of the niche for embryonic
hematopoietic sites. Are diverse properties attributed to embry-
onic, fetal, and adult HSCs due to differences in their respective
niches? To what extent are factors shared among different de-
velopmental or anatomical niches?
Transcription Factors in Hematopoietic Development
As intrinsic determinants of cellular phenotype, transcription fac-
tors provide an entry point for unraveling how HSCs develop dur-
ing embryogenesis and how lineage-restricted differentiation is
programmed (Orkin, 2000). Here we focus on principles and con-
cepts that have emerged and consider how these may inform
other organ/tissue systems. Recent reviews provide additional
discussion of transcription factors in different hematopoietic lin-
eages (Nutt and Kee, 2007; Iwasaki and Akashi, 2007; Kim and
Bresnick, 2007; Rothenberg, 2007). Insights into the functions
of the critical transcription factors have rested predominantly
on findings from either conventional or conditional gene knock-
Figure 3. Stem Cell Niche in the Adult Bone Marrow
HSCs are found adjacent to osteoblasts that are under the regulation of bone
morphogenetic protein (BMP) (the osteobast niche). HSCs are also found ad-
jacent to blood vessels (the vascular niche). The chemokine CXCL12 regulates
the migration of HSCs from the circulation to the bone marrow. The osteoblast
and vascular niches in vivo lie in close proximity or may be interdigitated. The
marrow space also contains stromal cells that support hematopoiesis includ-
ing the production of cytokines, such as c-Kit ligand, that stimulate stem cells
and progenitors. Cytokines, including interleukins, thrombopoietin (Tpo), and
erythropoietin (Epo), also influence progenitor function and survival.
636 Cell 132, 631–644, February 22, 2008 ª2008 Elsevier Inc.outs in mice and from forced expression experiments, all com-
plemented by developmental studies in other model organisms
(e.g., zebrafish, chicken,Drosophila, Xenopus). The transcription
factors that are critical for hematopoiesis encompass virtually all
classes of DNA-binding proteins, rather than favoring a specific
family. A remarkable feature of transcription factors in the hema-
topoietic system is that the majority are involved in chromosomal
translocations or with somatic mutations in human hematopoi-
etic malignancies. Furthermore, experimental manipulation of
the genes for such factors in mice often promotes malignancy.
Hematopoietic cell fate is intertwined with the origins of leuke-
mias. Requirements for several transcription factors, as estab-
lished through conventional gene targeting, are summarized in
Figure 4 (see also the SnapShot by S.H. Orkin and L.I. Zon,
page 631 of this issue).
For discussion purposes, one may distinguish between fac-
tors required for HSC formation or function and those employed
in lineage-specific differentiation. Among the ‘‘HSC transcription
factors’’ are MLL (for mixed lineage-leukemia gene), Runx1, TEL/
ETV6, SCL/tal1, and LMO2, whose genes account in toto for the
majority of known leukemia-associated translocations in pa-
tients. In these instances, the translocations either deregulate
expression of the locus, as in the case of SCL/tal1 and LMO2
in T cell acute leukemias, or generate chimeric fusion proteins,
as in myeloid and lymphoid leukemias associated with MLL,
Runx1, and TEL/ETV6. The above distinction is arbitrary in that
all of these HSC transcription factors also serve roles later within
differentiation of individual blood lineages, and conversely, fac-
tors that appear to have more lineage-restricted roles (such as
PU.1, Gfi-1,C/EBPa) act within HSCs. The redeployment of tran-
scription factors at different stages of blood cell development is
reflected in part in the dynamic patterns of expression of key reg-
ulators and complicates analysis of in vivo requirements. Both
temporal- and lineage-restricted conditional inactivation are of-
ten needed to reveal a meaningful phenotype. These circum-
stances reflect parsimony with regard to the repertoire of factors
required to achieve complex gene regulation and differentiation.
Factors Essential for Formation of HSCs
The transcription factors required to program mesoderm toward
a hematopoietic fate are of special interest. The basic-helix-
loop-helix (bHLH) factor SCL/tal-1 and its associated protein
partner, the Lim-domain containing LMO2, are individually es-
sential for development of both the primitive and definitive (or
adult) hematopoietic systems (Kim and Bresnick, 2007). In their
absence, no blood cells are generated. Within the primitive sys-
tem at the yolk sac stage, these factors are thought to function
within the hemangioblast to specify a blood rather than a vascular
fate. The genes encoding the SET-domain containing histone
methyltransferase MLL and runt-domain Runx1 proteins are es-
sential for generation of HSCs within the AGM (and possibly at
other sites) (Orkin, 2000). In the absence of Runx1, no hemato-
poietic clusters (representing presumptive HSCs) form in the
dorsal aorta in mice. As noted above, in zebrafish Runx1 lies
downstream of Notch signaling, which is required for the induc-
tion of hematopoiesis. In addition, BMP signaling restricts hem-
ato-vascular development of lateral mesoderm, possibly acting
through a pathway involving LMO2 and presumably GATA-2
(Burns et al., 2005). MLL, like itsDrosophila counterpart trithorax,
functions in maintenance of, but not initiation of, HOX gene ex-
pression. MLL also appears to lie upstream of HOXB4 (and pre-
sumably other HOX genes) in HSC specification. Leukemias in
which MLL function is perturbed due to chromosomal transloca-
tions may arise in part as a secondary consequence of changes
in HOX gene expression. Recently, it has been demonstrated
that expression of an MLL fusion gene (MLL-AF9) in granulo-
cyte/macrophage progenitors (GMPs) induces a ‘‘HSC stem
cell-like’’ signature that includes various HOX genes (Krivtsov
et al., 2006). The acquisition of a stem cell signature by leukemic
GMPs may contribute to self-renewal of leukemia stem cells.
Study of a zebrafish mutant defective for blood formation iden-
tified the caudal-related factor Cdx4 as an inducer of blood
specification (Davidson et al., 2003). Indeed, Cdx4-deficient em-
bryos are rescued by expression of various homeobox genes
(e.g., HoxA9) but not by SCL/tal1 (Yan et al., 2006). Activation
of Cdx4 expression in mouse ES cells alters the pattern of
HOX gene expression, augments in vitro blood formation, and
cooperates with HOXB4 in the generation of long-term reconsti-
tuting hematopoietic progenitors (Wang et al., 2005). Recent
evidence indicates that the pathway to Cdx4 in the zebrafish is
initiated by the TATA-box binding protein-related factor 3 (Trf3)
(Hart et al., 2007).
Temporal and Stage-Specific Requirements
for Hematopoietic Regulators
Within the definitive hematopoietic system, fetal liver and
bone marrow HSCs differ in many properties, including cell-
surface markers, developmental potential, and cell-cycle status.
Figure 4. Requirements of Transcription Factors in Hematopoiesis
The stages at which hematopoietic development is blocked in the absence of a given transcription factor, as determined through conventional gene knockouts,
are indicated by red bars. The factors depicted in black have been associated with oncogenesis. Those factors in light font have not yet been found translocated
or mutated in human/mouse hematologic malignancies. Abbreviations: LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem
cell; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progen-
itor; RBCs, red blood cells.
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Transplantation experiments in mice suggest that some charac-
teristics that distinguish fetal liver and adult HSCs are intrinsically
regulated (Bowie et al., 2007). Furthermore, HSCs in older age
mice exhibit different self-renewal and gene expression patterns
than those from younger animals (see Review by D. Rossi et al.,
page 681 of this issue). How the distinctive properties of HSCs at
different developmental stages are programmed is of particular
interest in correlating biological read-outs with molecular deter-
minants. Recently, the HMG-box containing factor Sox17, which
is also critical to endoderm specification, has been identified as
critical for generation of fetal, but not adult, HSCs (Kim et al.,
2007). ‘‘Geriatric’’ HSCs are less efficient at homing to and en-
grafting in the bone marrow, possibly linked to their increased
cycling frequency. In addition, the differentiation potential of
older HSCs is biased toward myeloid versus lymphoid lineages
(Sudo et al., 2000). Several changes in gene expression of old
versus young HSCs have been described, including increased
expression of leukemia-associated genes and decreased ex-
pression of genes contributing to DNA damage repair, genomic
integrity, and chromatin remodeling (Rossi et al., 2005; Nijnik
et al., 2007). Some of these properties are posited to predispose
older HSCs to myeloid leukemias (see Review by D. Rossi et al.).
Moreover, the transcription factors required for specification
and formation of HSCs may not be required continuously for
the subsequent survival or self-renewal of HSCs. Although
SCL/tal1 is an obligate factor for hematopoietic fate specification
during development, conditional inactivation in adult HSCs has
surprisingly little consequence on maintenance or self-renewal
of HSCs and multipotent progenitors (Mikkola et al., 2003). Un-
der these circumstances, the role of this factor in maturation of
erythroid and megakaryocytic cells is revealed. Similarly, inacti-
vation of Runx1 in adult HSCs does not ablate HSC properties
but instead perturbs differentiation of specific lineages (mega-
karyocytes, lymphocytes) (Ichikawa et al., 2004). Such observa-
tions point to differences in the transcription factor composition
of emerging HSCs and adult HSCs and suggest that the pheno-
type of HSCs is quite stable.
Multilineage Gene Expression in HSCs
Generally, the expression of the lineage-affiliated transcription
factors can be readily reconciled with the simple hierarchy dia-
grams of hematopoiesis (see Figures 1 and 4). For instance,
GATA-1 is highly expressed in megakaryocytic/erythroid pro-
genitors (called MEPs) that give rise to megakaryocyte and
red blood cell precursors, whereas a ‘‘myeloid factor,’’ such
as C/EBPa, is present in GMPs. Indeed, in committed progeni-
tors and precursors one can conveniently match cell-surface
phenotypes (defined by monoclonal antibodies) and the subset
of hematopoietic transcription factors expressed in these cells.
However, this relationship breaks down at earlier stages in the
hierarchy. A simple one-to-one correspondence of lineage-re-
stricted transcription factors and progenitors is challenged by
findings that earlier multipotential progenitors and HSCs ex-
press markers of disparate lineages even within single cells, al-
beit generally at low levels (Orkin, 2003). This phenomenon,
termed lineage priming, suggests that the fate of these imma-
ture cells is not sealed and that lineage selection is largely a pro-
cess in which alternative possibilities are extinguished rather
than one in which new programs are imposed on an otherwise
blank slate.
Lineage priming may be an efficient means by which chroma-
tin invested in important hematopoietic programs is maintained
in an available or open configuration in HSCs. Transient repres-
sion of alternative fates, followed by more permanent silencing,
maintains the inherent plasticity of multipotential progenitors.
Moreover, the coexistence of transcription factors representing
different lineages within a common cell (the HSC or immature
progenitor) offers the potential for immediate ‘‘crosstalk’’ be-
tween different fates at the molecular level (see below).
Recently, by FACS sorting of cells initiating expression GATA-
1 orPU.1, it has been demonstrated that short-term repopulating
HSCs may be further subdivided into those committed to mye-
loerythroid and myelolymphoid lineages (Arinobu et al., 2007).
As these findings illustrate, continued fractionation of HSC or
progenitor populations reveals increasing diversity in the choice
of lineage. Thus, the schematic lineage diagrams that are gener-
ally presented cannot be taken literally but rather as guides to the
options available to progenitors. The extent to which HSCs ex-
hibit developmental potential beyond hematopoiesis remains
controversial (Graf, 2002). Experiments purportedly demonstrat-
ing ‘‘plasticity’’ through transplantation of marrow cells to recip-
ient mice are plagued by possible cell fusion of differentiated
hematopoietic cells with host cells and by inadequate character-
ization of input populations.
Mechanisms of Action for Principal Hematopoietic
Regulators
The requirements and functions of the principal transcriptional
regulators are context dependent (Orkin, 2000). The key line-
age-restricted factors are endowed with the complementary
tasks of promoting their own lineage differentiation while simul-
taneously acting against factors favoring other choices (Figure 5).
Combining positive and antagonistic roles in the major regulators
provides an efficient means for resolving and reinforcing lineage
Figure 5. Transcription Factor Antagonism in Lineage Determina-
tion
Examples of antagonism are depicted in red. The transcription factors present
in the mature precursors following choice of specific lineage are shown at the
bottom in black. Abbreviations: CMP, common myeloid progenitor; MEP,
megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progen-
itor; RBCs, red blood cells.
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choices. Numerous examples of this principle of lineage pro-
gramming have been described. GATA-1 and PU.1 promote ery-
throid/megakaryocytic/eosinophil and myeloid differentiation,
respectively. The proteins physically interact and antagonize
each other’s actions. In vivo confirmation of the complementary
roles of GATA-1 and PU.1 has been shown in zebrafish. Inhibi-
tion of GATA-1 expression by morpholinos shifts hematopoietic
progenitors to a myeloid fate, whereas the converse occurs upon
inhibition of PU.1 expression (Galloway et al., 2005; Rhodes
et al., 2005). Other examples of direct antagonism by hematopoi-
etic transcription factors include the relative relationships of C/
EBP and FOG1 with respect to eosinophil and multipotential
cell fates (Querfurth et al., 2000), EKLF and Fli-1 for erythroid
and megakaryocytic choice (Starck et al., 2003), GATA-3 and
T-bet for TH1 and TH2 cells (Usui et al., 2006), and Gfi1 and
PU.1 for neutrophil versus monocyte outcomes (Dahl et al.,
2007). In the absence of Gfi1 in mice, neutrophil precurors fail
to mature and also incompletely silence monocyte/macrophage
gene expression (Hock et al., 2003).
The critical contribution of repression to lineage selection is il-
lustrated by loss-of-function studies ofPax5. Proper B cell devel-
opment requires Pax5 (Nutt and Kee, 2007). In its absence, proB
cells assume a multipotential phenotype and differentiate (under
appropriate growth factor conditions) to T-, NK-, or dendritic
cells, macrophages, neutrophils, or erythroid precursors. Re-
pression of critical growth factor receptors, for example macro-
phage-colony-stimulating factor (M-CSF) receptor, restricts line-
age choice during normal development. In effect, Pax5 commits
progenitors to a B cell fate, while other B cell transcription fac-
tors, such as E2A and EBP, specify lineage-appropriate gene
activation.
In T-lymphoid development, Notch signaling serves a similar
but more focused role as it functions as a commitment factor,
principally by repressing factors, such as PU.1, associated
with other outcomes. Although GATA-3 has been viewed as
a T cell-specific transcription factor, recent work indicates that
it functions only in the context of Notch signaling to promote T
cell development (Rothenberg, 2007). As recently stated, lineage
programming in the T cell lineage is more the consequence of
‘‘negotiation’’ rather than instruction.
Mechanisms of Lineage Programming
The context-dependent action and direct antagonism between
key transcriptional regulators are best accommodated by
models in which factors interact directly within protein com-
plexes (Orkin, 2000). In this regard, the GATA factors are illustra-
tive (Kim and Bresnick, 2007). A protein complex in erythroid
cells comprised of GATA-1 (or its close relative, GATA-2),
LMO2 and its partner Ldb1, and SCL/tal1 and its heterodimeric
partner E2A recognizes a consensus GATA-E-box DNA motif.
Knockout of either LMO2 or SCL/tal1 leads to the absence of
any hematopoietic progenitors in the early embryo. The identical
phenotypes are consistent with the action of these proteins
within a single complex that is required prior to any commitment
to erythroid differentiation. Indeed, forced expression of GATA-
1/2, SCL, and LMO2 converts Xenopus mesoderm efficiently
to a hematopoietic fate. Remarkably, although the GATA/SCL/
LMO2/Lbd1 complex recognizes a composite DNA-binding
site, later studies demonstrated that the DNA-binding activityof SCL (in a heterodimer with E2A) is dispensable for hematopoi-
etic specification but required for full erythroid and megakaryo-
cytic cell maturation (Porcher et al., 1999). The recruitment of
DNA-binding-defective SCL to the protein complex accounts
for in vivo function despite its inability to bind to DNA.
GATA factors form alternative protein complexes with a spe-
cific cofactor known as FOG (for friend of GATA) (Kim and Bres-
nick, 2007). Targeted mutation in mice has demonstrated the es-
sential role of the GATA/FOG interaction for erythroid and
megakaryocytic development. The GATA-1 (or GATA-2)/FOG1
complex in both erythroid and megakaryocytic lineages is phys-
ically associated with the NuRD chromatin remodeling complex
via an NuRD binding motif at the N terminus of FOG1. The inter-
action of FOG1 with GATA factors mediates transcription repres-
sion and also may facilitate accessibility of the GATA factor to its
DNA-binding motif in chromatin. GATA/SCL/LMO2/Ldb1 and
GATA/FOG1 complexes appear to be mutually exclusive.
Other connections between hematopoietic factors and chro-
matin-associated proteins amplify this theme. Ikaros proteins
also associate with the NuRD complex and participate in repres-
sion and the formation of heterochromatin (Kim et al., 1999). The
erythroid factor EKLF interacts with Brg1, a critical component of
the Swi/Snf ATP-dependent chromatin remodeling complex
(Brown et al., 2002). Consistent with the relevance of this rela-
tionship to biological function, a Brg1 mutant protein, which re-
tains ATPase activity and assembles into the Swi/Snf complex,
fails to generate DNase I hypersensitivity and leads to embryonic
lethality due to failure to activate normal b-globin expression
(Bultman et al., 2005). Furthermore, another erythroid factor
NF-E2 associates with the MLL2 complex, which is responsible
for H3K4 histone methylation (Demers et al., 2007). In addition,
the zinc-finger repressor Gfi protein recruits a CoREST/lysine
demethylase (LSD1) complex to target genes in erythroid, mega-
karyocytic, and myeloid cells to control maturation of these line-
ages (Saleque et al., 2007). Further elucidation of the ways in
which hematopoietic transcription factors interact and function
with chromatin-associated factors in HSCs and individual line-
ages is an on-going challenge for the field.
The involvement of multiprotein complexes in the action of he-
matopoietic transcription factors predicts that relative concen-
trations of particular factors should influence the choice of line-
age. Protein complexes constitute a convenient platform for
direct competition, as well as for cooperative action. Consider-
able data argue for concentration-dependent effects in lineage
choice and differentiation. Experiments in zebrafish cited above
in which the pattern of erythroid versus myeloid development is
affected by inhibition of expression ofGATA-1 or PU.1 (Galloway
et al., 2005; Rhodes et al., 2005) are consistent with this model.
The relative action of GATA-1 and PU.1 fits a simple quantitative
model that predicts a metastable undifferentiated progenitor
state when both proteins are present at low levels and differen-
tiation to one of two alternatives when one of the proteins is pres-
ent at higher levels (Roeder and Glauche, 2006). Taking advan-
tage of PU.1-null fetal liver progenitors, Singh and colleagues
have proposed that high-level PU.1 expression directs macro-
phage differentiation, whereas low-level expression promotes
B cell formation (DeKoter and Singh, 2000). Subsequently,
they proceeded to show that low-level PU.1-expressing
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bi-phenotypic (macrophage/neutrophil) cells are relatively sta-
ble, and increased PU.1 levels promote macrophage differentia-
tion by influencing a circuit of counterantagonistic repressors,
Egr-1/2/Nab-2 and Gfi1 (Laslo et al., 2006). A mathematical
model, similar to that described above for GATA-1 and PU.1,
has been derived to account for these observed effects in the
two myeloid lineages.
MicroRNAs (miRNAs) provide an additional level of control be-
yond the transcription factors (Shivdasani, 2006) (see Minireview
by B. Stadler and H. Ruohola-Baker, page 563 of this issue). On-
going studies of the involvement of miRNAs in hematopoiesis will
reveal their roles in lineage decisions, stem cell to progenitor
transitions, niche control, and cell function. The transcription of
blood cell-specific miRNAs is likely to be driven by the com-
plexes discussed above, providing a complex regulatory net-
work. Several miRNAs are highly expressed in specific hemato-
poietic lineages and manipulation of their levels has been
correlated with changes in cellular properties or differentiation
(Chen et al., 2004). For example, miR-150 impinges on B cell dif-
ferentiation by targeting c-myb mRNA (Xiao et al., 2007),
whereas miR-155 is required for T helper cell generation and ger-
minal center activity (Rodriguez et al., 2007; Thai et al., 2007).
Moreover, conditional inactivation of the gene encoding Dicer,
an essential component in the processing of pre-miRNAs to
miRNAs, leads to multiple defects in T-lineage lymphopoiesis
(Muljo et al., 2005; Cobb et al., 2006). Unpublished experiments
indicate that Dicer is also required in the setting of bone marrow
transplantation for radioprotection of lethally irradiated recipient
mice (cited in Martinez and Busslinger, 2007).
Lineage Reprogramming
Cellular differentiation was once considered unidirectional, that
is, once progenitors have committed to a particular linear path-
way their fate is sealed. Accumulating evidence in the hemato-
poietic system and in other systems (see Review by R. Jaenisch
and R. Young, page 567 of this issue) dispels this notion and pro-
vides a strong foundation for cellular reprogramming. Indeed,
cells of one hematopoietic lineage can be converted to another
through the forced expression of carefully chosen transcription
factors (Figure 6). Knowledge of the rules governing how tran-
scription factors that direct cellular lineages act informs directed
attempts to reprogram one lineage to another. In an early exam-
ple based on such logic, Querfurth et al. (2000) queried the sig-
nificance of the lack of FOG-1 in eosinophils, despite their de-
pendence on GATA-1 for differentiation. Forced expression of
FOG-1 in avian eosinophils downregulated expression and func-
tion of C/EBPb, an essential eosinophil factor, leading to acqui-
sition of a multipotent phenotype. Conversely, downregulation of
FOG-1 by C/EBPb is a critical step in eosinophil lineage commit-
ment. In other experiments, forced expression of GATA-1 was
shown to drive early myeloid avian progenitors to erythroid,
eosinophilic, or thromboblastic (megakaryocytic) precursors
(Kulessa et al., 1995). Moreover, introduction of GATA-1 into
GMPs and common lymphoid progenitors redirects their com-
mitment to megakaryocytic/erythroid progenitors or to erythroid
cells/mast cells/basophils (Iwasaki and Akashi, 2007). Commit-
ted B- and T-lymphoid cells can be reprogrammed to functional
macrophages through expression ofC/EBPa (Laiosa et al., 2006;
Xie et al., 2004). Furthermore, preT cells can be reprogrammed
to myeloid dendritic cells through PU.1 expression. Cells that
are reprogrammed transit through an intermediate state in which
markers of both myeloid and lymphoid lineages are expressed,
indicative of the stepwise nature of the process. Resolution of
the intermediate state leads to stable unilineage differentiation.
Notch and GATA-3 appear to counteract reprogramming of
preT cells to macrophages or dendritic cells. Recently, GATA-
3, traditionally viewed as a T cell-restricted factor, has been
shown to direct mast cell reprogramming from proT cells (Ta-
ghon et al., 2007). In addition, mid-stage thymocytes (at the
DN2 stage) can be converted to mast cells through growth in cul-
ture medium containing interleukin (IL)-3 and stem cell factor
(Kit-ligand) in the absence of Notch.
Cancer: A Perturbation of the Hematopoietic
Transcriptional Network
Of the more than two dozen regulators designated ‘‘hematopoi-
etic transcription factors,’’ nearly all are intimately associated
with hematopoietic malignancy (Figure 4). Indeed, the majority
of genes encoding these factors were discovered either through
analysis of chromosomal translocations found in human leuke-
mias or study of cooperating leukemia genes during insertional
mutagenesis in the mouse. Disturbance of the homeostatic bal-
ance of the critical transcriptional regulators is a defining feature
of leukemias. In the setting of chromosomal translocations that
lead to misexpression of a factor, such as SCL/tal1 or LMO2, tar-
get genes may be inappropriately activated or repressed in early
lymphoid progenitors. Chimeric transcription factors generated
through chromosomal translocations exert multiple downstream
effects, including improper target gene activation or repression,
Figure 6. Reprogramming of Hematopoietic Lineages
The orange arrows depict lineage reprogramming upon expression of the tran-
scription factors GATA-1, C/EBP, or GATA-3. Abbreviations: HSC, hemato-
poietic stem cell; CMP, common myeloid progenitor; CLP, common lymphoid
progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/
macrophage progenitor.
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inhibition of function of other critical factors, and recruitment of
alternative chromatin-modifying enzymes to target loci (Rose-
nbauer and Tenen, 2007). Leukemia is not the consequence of
nonspecific transcriptional effects but rather the end result of at-
tacks at vulnerable points in a network. This observation is best
exemplified by somatic mutations in GATA-1 in Down Syn-
drome-associated megakaryocytic leukemia (Wechsler et al.,
2002), PU.1 and C/EBPa in myeloid leukemias (Mueller et al.,
2002; Pabst et al., 2001), and Pax5 and other B cell factors (for
example, E2A and EBF) in B-lymphoid leukemias (Mullighan
et al., 2007). In addition to somatic mutation of the principal he-
matopoietic transcription factors, lesions in more broadly utilized
signaling pathways that control specific lineage differentiation
may underlie hematopoietic malignancy. This circumstance is il-
lustrated by consistent somatic mutation ofNotch in T cell leuke-
mias (Weng et al., 2004). As an essential component of the reg-
ulatory network for T cell commitment and development, Notch
is a preferred target for somatic mutation in T cell leukemia.
Messages for the Wider Stem Cell Field
As arguably the most ‘‘mature’’ organ system under study, the
hematopoietic system constitutes a model for other subfields
of stem cell biology. The hematopoietic system continues to
evolve as a model, however, as numerous critical issues remain
to be addressed. It is likely that many of the concepts derived
from work in the blood field will be revisited in other organ sys-
tems. Nonetheless, it is also apparent that nature has explored
alternative pathways to tissue organization and development.
Hence, differences should be anticipated, particularly with re-
spect to the extent to which true stem cells are required for the
maintenance of different tissues or cell populations within an or-
gan. Adult stem cell populations are generated during embryo-
genesis. For other organs, distinct stage-specific programs reg-
ulate stem cell homeostasis and tissue differentiation. As
illustrated by umbilical cord blood stem cells, transient popula-
tions may have therapeutic value. Reflection on the history and
recent advances in the hematopoietic field leads to several ‘‘les-
sons’’ for the stem cell field:
 Precise characterization of the cells within the hematopoietic
hierarchy has been instrumental in providing an adequate frame-
work for biological and molecular studies. The prospective isola-
tion of subsets of cells, coupled with in vitro colony-forming
assays and quantitative in vivo transplantation methods, has
greatly facilitated molecular studies of both normal and malig-
nant hematopoiesis. HSCs differ in their properties depending
on their location (fetal liver, bone marrow, placenta) and on the
age of the organism. Hence, thorough cell biological studies
are fundamental to approaching mechanisms that regulate
stem cell function.
 The ‘‘classical’’ hierarchy diagram depicting progenitors
arising in an orderly fashion from a prototypical HSC provides
a seductive, but overly simplified view. HSCs may be described
more accurately as groups of cells with varying developmental
potentials based on intrinsic networks driven by transcription
factors and inputs from the cellular niches in which they reside.
Processes, such as lineage priming coupled with plastic deci-
sions driven by transcription factor competition, confer great
flexibility on the options of HSCs. The molecular events of self-renewal must be coordinated with these steps. Current views
of HSCs must account for a spectrum of cells with varying en-
graftment potential and distinct biases toward subsequent mye-
loid or lymphoid lineage choices. These complex features of
HSC biology are likely to be revisited in studies of other tissue-
dedicated stem cells.
 Parallel investigation in diverse species has accelerated an
understanding of blood cell development. Although an important
goal is application of fundamental knowledge of hematopoietic
stem cell biology to the treatment of human disease, studies in
mice, fish, and flies are mutually reinforcing. Although the ana-
tomical features of blood formation in the latter organisms differ
from that of mammals, critical growth factor signaling and tran-
scriptional pathways are shared. Parallel investigation of differ-
ent species takes advantage of the strengths of each and com-
plements work with human hematopoietic cells.
 Elucidation of the transcriptional network that controls line-
age choice and differentiation sets the stage for directed reprog-
ramming of cellular lineages. Knowing the principal factors that
govern the cellular lineages identifies candidate regulators for
functional testing. Further study of the sequence of molecular
events accompanying lineage conversion is likely to provide im-
portant mechanistic clues regarding how complex cellular re-
programming occurs (Rossant, 2007).
 The remarkable link between hematopoietic transcription
factors and malignancy underscores how disturbance of a tran-
scriptional network lies at the crux of oncogenesis. As most he-
matopoietic transcription factors were discovered through study
of chromosomal translocations in leukemia, investigators should
pursue the normal developmental functions of genes disrupted
or brought into fusion products in various solid tumors, both in
sarcomas and epithelial cancers, given the recent appreciation
for the importance of translocations in these settings. More gen-
erally, the transcriptional regulators participating in cell-specific
gene expression provide entry points into the transcriptional net-
work controlling self-renewal and differentiation, the hallmarks of
stem cells.
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